| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $435K | — | -24.5% |
| SG&A Expense | $1.2M | — | -20.3% |
| Operating Income | -$1.6M | — | +21.5% |
| Net Income | -$1.6M | — | +21.0% |
| EPS (Basic) | -$0.12 | — | +42.9% |
| EPS (Diluted) | -$0.12 | — | +42.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.1M | +132.7% | +33.6% |
| Current Assets | $5.3M | +105.7% | +30.2% |
| Total Assets | $5.5M | +97.2% | +35.6% |
| Current Liabilities | $652K | -3.0% | -22.3% |
| Total Liabilities | $652K | -3.0% | -22.3% |
| Stockholders' Equity | $4.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.7M | — | +5.8% |
| Financing Cash Flow | $4.6M | — | +2698.1% |
| +50.5% |